Summer 2026
Summer 2026 Service Solutions Intern
Posted on 1/5/2026
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
No salary listed
No H1B Sponsorship
Palm Beach Gardens, FL, USA
In Person
 Operations & Logistics (2) |
|---|
| , |
- Currently pursuing a bachelor’s or master’s degree in engineering; must have completed at least sophomore year before internship starts.
- Minimum GPA: 3.0.
- Verbal and Written Communication Skills: Strong ability to communicate technical information clearly to diverse stakeholders.
- Problem Solving: Basic analytical skills to identify issues and implement solutions that enhance quality and service operations.
- Permanently authorized to work in the United States, must not require sponsorship of an employment visa at the time of application or in the future; Students on CPT, OPT, or STEM OPT usually require future sponsorship for long-term employment and do not meet requirements for this program unless eligible for an alternative long-term status that does not require company sponsorship.
- Complete projects (varied by function) either independently or as part of a team, involving strategic business issues.
- Present final project(s) to key stakeholders in the department.
- Work with teams like Research and Development, Manufacturing, and Quality to help develop and improve products.
- Assist in creating helpful documents such as user guides, troubleshooting tips, training materials, and reports.
- Help identify ways to improve product quality and serviceability using process improvement tools.
- Communicates relevant business-related issues and opportunities to the next management level to facilitate informed decision-making.
- Responsible for communicating business-related issues or opportunities to next management level
- Responsible for following all Company guidelines related to Health, Safety and Environmental practices as applicable.
- For those who supervise or manage a staff, responsible for ensuring that subordinates follow all Company guidelines related to Health, Safety and Environmental practices and that all resources needed to do so are available and in good condition, if applicable
- Responsible for ensuring personal and Company compliance with all Federal, State, local and Company regulations, policies, and procedures.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Simplify's Take
What believers are saying
- Icotyde launches with 1,500 prescriptions, Guggenheim projects $14.9 billion peak sales.
- Atraverse Medical acquisition bolsters HOTWIRE system for atrial fibrillation ablations.
- ETHICON 4000 Stapler gains CE Mark, reducing surgical leaks costing €5,200 per case.
What critics are saying
- Stelara sales plummet 60% to $656 million from Amgen and Samsung biosimilars.
- Over 90,000 talc lawsuits trigger $966 million October 2025 verdict against J&J.
- CARVYKTI manufacturing shortfalls cap multiple myeloma sales growth in 2026.
What makes Johnson & Johnson unique
- Diversified revenue spans Innovative Medicine, MedTech, and consumer health segments.
- DARZALEX sales hit $4 billion in Q1 2026, exceeding forecasts by $600 million.
- CARTO System marks 30 years, powering AI-driven CARTOSOUND SONATA for electrophysiology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Company News
Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.
Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.
Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.
Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.
Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.